Changing fashions, cultural attitudes and health beliefs have contributed to the rise of deadly melanoma skin cancer, according to a new study.
Health Canada Approves Yervoy® (Ipilimumab) For First-line Treatment of Adults With Metastatic Melanoma, the Most Deadly Form of Skin Cancer
Bristol-Myers Squibb Canada is pleased to announce that Health Canada has approved Yervoy® (ipilimumab) as a first-line therapy in adults with unresectable or metastatic melanoma, the most deadly form of skin cancer. This means that Canadians with newly diagnosed advanced melanoma, regardless of the subtype, will be eligible to receive the novel immunotherapy as their initial treatment.
Amgen has applied for European Medicines Agency approval of an investigational oncolytic immunotherapy for the treatment of regionally or distantly metastatic melanoma.
Writers in the recent issue of JAMA Dermatology call on the healthcare system to change the way the nation screens for melanoma, citing the $291 million annual cost of treating the disease and the $2.85 billion costs in lost productivity, which authors say could be trimmed if cases were caught earlier.
A study in Australia examined patient and tumor characteristics for melanomas with higher mitotic rates (a marker of tumor cell growth) in an effort to increase earlier detection of this aggressive cancer in patients. August 20, 2014
Patients taking a BRAF inhibitor are more susceptible to highly volatile melanocytic lesions that make the detection of new primary melanomas more difficult, according to results shared in a research letter published in JAMA: Dermatology. August 4, 2014